Background: Chronic asymptomatic Plasmodium falciparum infections are common in endemic areas and are thought to contribute to the maintenance of malaria immunity. Whether treatment of these infections increases the subsequent risk of clinical episodes of malaria is unclear. Methods: In a 3-year study in Mali, asymptomatic individuals with or without P. falciparum infection at the end of the 6-month dry season were identified by polymerase chain reaction (PCR), and clinical malaria risk was compared during the ensuing 6-month malaria transmission season. At the end of the second dry season, 3 groups of asymptomatic children were identified: (1) children infected with P. falciparum as detected by rapid diagnostic testing (RDT) who were treated with antimalarials (n = 104), (2) RDT-negative children whose untreated P. falciparum infections were detected retrospectively by PCR (n = 55), and (3) uninfected children (RDT/PCR negative) (n = 434). Clinical malaria risk during 2 subsequent malaria seasons was compared. Plasmodium falciparum-specific antibody kinetics during the dry season were compared in children who did or did not harbor asymptomatic P. falciparum infections. Results: Chronic asymptomatic P. falciparum infection predicted decreased clinical malaria risk during the subsequent malaria season(s); treatment of these infections did not alter this reduced risk. Plasmodium falciparum-specific antibodies declined similarly in children who did or did not harbor chronic asymptomatic P. falciparum infection during the dry season. Conclusions: These findings challenge the notion that chronic asymptomatic P. falciparum infection maintains malaria immunity and suggest that mass drug administration during the dry season should not increase the subsequent risk of clinical malaria. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Chronic asymptomatic Plasmodium falciparum infections are common in endemic areas and are thought to contribute to the maintenance of malaria immunity. Whether treatment of these infections increases the subsequent risk of clinical episodes of malaria is unclear. Methods: In a 3-year study in Mali, asymptomatic individuals with or without P. falciparum infection at the end of the 6-month dry season were identified by polymerase chain reaction (PCR), and clinical malaria risk was compared during the ensuing 6-month malaria transmission season. At the end of the second dry season, 3 groups of asymptomatic children were identified: (1) children infected with P. falciparum as detected by rapid diagnostic testing (RDT) who were treated with antimalarials (n = 104), (2) RDT-negative children whose untreated P. falciparum infections were detected retrospectively by PCR (n = 55), and (3) uninfected children (RDT/PCR negative) (n = 434). Clinical malaria risk during 2 subsequent malaria seasons was compared. Plasmodium falciparum-specific antibody kinetics during the dry season were compared in children who did or did not harbor asymptomatic P. falciparum infections. Results: Chronic asymptomatic P. falciparum infection predicted decreased clinical malaria risk during the subsequent malaria season(s); treatment of these infections did not alter this reduced risk. Plasmodium falciparum-specific antibodies declined similarly in children who did or did not harbor chronic asymptomatic P. falciparum infection during the dry season. Conclusions: These findings challenge the notion that chronic asymptomatic P. falciparum infection maintains malaria immunity and suggest that mass drug administration during the dry season should not increase the subsequent risk of clinical malaria. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Plasmodium falciparum; asymptomatic; malaria; malaria/drug therapy; mass drug administration.
Authors: Sándor Bereczky; Anne Liljander; Ingegerd Rooth; Lea Faraja; Fredrik Granath; Scott M Montgomery; Anna Färnert Journal: Microbes Infect Date: 2006-12-06 Impact factor: 2.700
Authors: Onome J Akpogheneta; Nancy O Duah; Kevin K A Tetteh; Samuel Dunyo; David E Lanar; Margaret Pinder; David J Conway Journal: Infect Immun Date: 2008-01-22 Impact factor: 3.441
Authors: David A Larsen; Adam Bennett; Kafula Silumbe; Busiku Hamainza; Joshua O Yukich; Joseph Keating; Megan Littrell; John M Miller; Richard W Steketee; Thomas P Eisele Journal: Am J Trop Med Hyg Date: 2015-03-23 Impact factor: 2.345
Authors: S Bhatt; D J Weiss; E Cameron; D Bisanzio; B Mappin; U Dalrymple; K Battle; C L Moyes; A Henry; P A Eckhoff; E A Wenger; O Briët; M A Penny; T A Smith; A Bennett; J Yukich; T P Eisele; J T Griffin; C A Fergus; M Lynch; F Lindgren; J M Cohen; C L J Murray; D L Smith; S I Hay; R E Cibulskis; P W Gething Journal: Nature Date: 2015-09-16 Impact factor: 49.962
Authors: J Teun Bousema; Louis C Gouagna; Chris J Drakeley; Annemiek M Meutstege; Bernard A Okech; Ikupa N J Akim; John C Beier; John I Githure; Robert W Sauerwein Journal: Malar J Date: 2004-06-17 Impact factor: 2.979
Authors: Andrea G Buchwald; Alick Sixpence; Mabvuto Chimenya; Milius Damson; John D Sorkin; Mark L Wilson; Karl Seydel; Sarah Hochman; Don P Mathanga; Terrie E Taylor; Miriam K Laufer Journal: Clin Infect Dis Date: 2019-01-01 Impact factor: 9.079
Authors: Omid Taghavian; Aarti Jain; Chester J Joyner; Sunny Ketchum; Rie Nakajima; Algis Jasinskas; Li Liang; Rich Fong; Christopher King; Bryan Greenhouse; Maxwell Murphy; Jason Bailey; Mary R Galinski; John W Barnwell; Christopher V Plowe; D Huw Davies; Philip L Felgner Journal: Proteomics Date: 2018-01 Impact factor: 3.984
Authors: Stephanie I Studniberg; Lisa J Ioannidis; Retno A S Utami; Leily Trianty; Yang Liao; Waruni Abeysekera; Connie S N Li-Wai-Suen; Halina M Pietrzak; Julie Healer; Agatha M Puspitasari; Dwi Apriyanti; Farah Coutrier; Jeanne R Poespoprodjo; Enny Kenangalem; Benediktus Andries; Pak Prayoga; Novita Sariyanti; Gordon K Smyth; Alan F Cowman; Ric N Price; Rintis Noviyanti; Wei Shi; Alexandra L Garnham; Diana S Hansen Journal: Mol Syst Biol Date: 2022-04 Impact factor: 13.068
Authors: Anouk von Borstel; Priyanka Chevour; Daniel Arsovski; Jelte M M Krol; Lauren J Howson; Andrea A Berry; Cheryl L Day; Paul Ogongo; Joel D Ernst; Effie Y H Nomicos; Justin A Boddey; Edward M Giles; Jamie Rossjohn; Boubacar Traore; Kirsten E Lyke; Kim C Williamson; Peter D Crompton; Martin S Davey Journal: Sci Transl Med Date: 2021-12-01 Impact factor: 19.319
Authors: Jacob E Schrum; Juliet N Crabtree; Katherine R Dobbs; Michael C Kiritsy; George W Reed; Ricardo T Gazzinelli; Mihai G Netea; James W Kazura; Arlene E Dent; Katherine A Fitzgerald; Douglas T Golenbock Journal: J Immunol Date: 2018-01-12 Impact factor: 5.422
Authors: Carolina M Andrade; Hannah Fleckenstein; Richard Thomson-Luque; Safiatou Doumbo; Nathalia F Lima; Carrie Anderson; Julia Hibbert; Christine S Hopp; Tuan M Tran; Shanping Li; Moussa Niangaly; Hamidou Cisse; Didier Doumtabe; Jeff Skinner; Dan Sturdevant; Stacy Ricklefs; Kimmo Virtaneva; Muhammad Asghar; Manijeh Vafa Homann; Louise Turner; Joana Martins; Erik L Allman; Marie-Esther N'Dri; Volker Winkler; Manuel Llinás; Catherine Lavazec; Craig Martens; Anna Färnert; Kassoum Kayentao; Aissata Ongoiba; Thomas Lavstsen; Nuno S Osório; Thomas D Otto; Mario Recker; Boubacar Traore; Peter D Crompton; Silvia Portugal Journal: Nat Med Date: 2020-10-26 Impact factor: 87.241